Ratings Modulight Oyj

Equities

MODU

FI4000511506

Market Closed - Nasdaq Helsinki Other stock markets 08:45:18 26/04/2024 pm IST			5-day change	1st Jan Change
0.826 ^EUR	-8.93%		-9.23%	-29.64%

24/02	Modulight Oyj Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
23/02	Transcript : Modulight Oyj, 2023 Earnings Call, Feb 23, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's share price in relation to its net book value makes it look relatively cheap.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's enterprise value to sales, at 4.42 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MODULIGHT OYJ	-29.64%	37.54M		-
CLINICAL LASERTHERMIA SYSTEMS AB	-37.75%	12.3M		-
EL.EN. S.P.A.	+19.38%	994M		B+
SISRAM MEDICAL LTD	-32.70%	212M		-
LASEROPTEK CO., LTD.	-35.85%	74.33M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes